RxMP Therapeutics Announces Opening of $2 Million Bridge Financing Round
RxMP Therapeutics is announcing the opening of a $2 million bridge financing round to support the next phase of development for its lead hemostatic platform. The round already has over $1.2M committed, led by a $750,000 investment from the Wallace H. Coulter Foundation, the company’s largest shareholder and long-time partner. This strong early support, including additional investment in this round by insiders, underscores continued confidence in RxMP’s mission and progress toward delivering a life-saving hemorrhage control solution.
Over the past year, RxMP has made significant traction across both manufacturing and regulatory milestones. The company has advanced its GMP manufacturing plans and strengthened its regulatory pathway, while continuing to refine its strategy for early commercialization opportunities. This includes exploration of potential Emergency Use Authorization (EUA) pathways in collaboration with the Department of Defense, reflecting the urgent and mission-critical need for effective hemorrhage control technologies in military and emergency settings.
Proceeds from the bridge round will be used to support GMP manufacturing required for remaining IND-enabling animal studies and the planned Phase I clinical trial. With this financing, RxMP aims to maintain development momentum, de-risk upcoming regulatory milestones, and position the company for subsequent clinical and commercialization phases.
RxMP Therapeutics is a pre-clinical biotechnology company developing novel therapies for the rapid control of severe hemorrhage. Its lead product candidate, RMP-402, is a first-in-class hemostatic therapeutic derived from a naturally occurring red blood cell byproduct and is designed to rapidly stop bleeding without increasing the risk of thrombosis. RMP-402 is being developed for use in both civilian and military settings, addressing a global trauma and surgical bleeding market estimated to exceed several billion dollars annually, where uncontrolled bleeding remains a leading cause of preventable death.